Floatz logo

Bbo-8520

Advanced Lung Carcinoma

TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)Phase 1Active
CC
41/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
81/ 100

Competitive context

67 Active assets in the Advanced Lung Carcinoma cohort.

Asset / SponsorPhaseRating
CIS-DIAMMINEDICHLOROPLATINUM II
Taiho Oncology, Inc.
Phase 3BB
OTL-38
On Target Laboratories, LLC
Phase 4BB
ETOPOSIDE
SystImmune Inc.
Phase 3BB
Nivolumab
M.D. Anderson Cancer Center
Phase 2B
Carboplatin
SystImmune Inc.
Phase 3B

View all 50 →

Same molecule, other indications

Bbo-8520 is also rated in:

lung cancerDormant
CC
Indicative ·
43 / 100
View asset →
KRAS G12CDormant
CC
Indicative ·
41 / 100
View asset →
non-small cell lung carcinomaDormant
C
Indicative ·
36 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →